LRRK2-IN-7

• CAT Number: I042286
• CAS Number: 2307277-93-4
• Molecular Formula: C24H26N6O
• Molecular Weight: 414.50
• Purity: ≥95%
• Synonyms: (2S)-2-[1-[6-[(3R)-3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl]pyrimidin-4-yl]indazol-6-yl]spiro[2.2]pentane-2-carbonitrile
• InChI: InChI=1S/C24H26N6O/c1-22(2,31)18-5-8-29(12-18)20-10-21(27-15-26-20)30-19-9-17(4-3-16(19)11-28-30)24(14-25)13-23(24)6-7-23/h3-4,9-11,15,18,31H,5-8,12-13H2,1-2H3/t18-,24-/m1/s1
• InChIKey: JCQABEJXHUSDMF-HOYKHHGWSA-N
• SMILES: CC(C)([C@@H]1CCN(C1)C2=NC=NC(=C2)N3C4=C(C=CC(=C4)[C@@]5(CC56CC6)C#N)C=N3)O

LRRK2-IN-7（Cat No.:I042286）is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), a protein implicated in the pathogenesis of Parkinson’s disease. LRRK2 is involved in regulating various cellular processes, including autophagy, and mutations in LRRK2 have been linked to the development of familial and sporadic Parkinson’s disease. By inhibiting LRRK2, LRRK2-IN-7 aims to reduce neurodegenerative processes, including inflammation and impaired cellular function, associated with Parkinson’s. Preclinical studies suggest that LRRK2-IN-7 may help protect dopaminergic neurons, offering potential as a therapeutic candidate for treating Parkinson’s disease.